Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Audit Management

Audit Management

View Detailed Analysis

Analytics Overview

17
Form 483s Issued
1
483s converted to WL
17
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
20 Sep 2024
Aarti Drugs Limited
Drugs
26 Jul 2024
Biocon Biologics Limited
Drugs
24 May 2024
Mylan Laboratories Limited
Drugs
05 Apr 2024
Eugia Steriles Private Limited
Drugs
29 Feb 2024
Eugia SEZ Private Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
4
0
Teresa I Navas
2
0
Arsen Karapetyan
1
0
Brandon L Mariner
1
0
Ashar P Parikh
1
0
TITLE/ COMPANY Issue Date Status Details
Your internal audit is not effective to verify compliance with the principles of CGMP for APIs.
Aarti Drugs Limited
20 Sep 2024 Normal Justification: Audit Management is directly linked as the observation highlights deficiencies in the audit execution and auditor qualifications.
Excerpt: Your firm’s internal audit is not robust and are all preannounced audits based on a predefined checklist.
View Details
Computerized systems lack controls and review of electronic data to prevent omissions in data.
Biocon Biologics Limited
26 Jul 2024 Normal Justification: The failure to have detailed, software-specific audit procedures directly affects the completeness and accuracy of data reviews.
Excerpt: Audit trail review procedures for production software are general and do not contain instructions specific to the different software to ensure a thorough review of raw data.
View Details
Records associated with drug product production and control and within the retention period for such records, were not made readily available for authorized inspection.
Mylan Laboratories Limited
24 May 2024 Normal Justification: Audit Management pertains to the observation due to complications in provision and management of audit-related documents.
Excerpt: These events and interactions detailed in this section introduced a delay in our ability to perform the remainder of the inspection in a timely and effective manner.
View Details
Input to and output from the computer and records or data are not checked for accuracy.
Eugia Steriles Private Limited
05 Apr 2024 Normal Justification: Audit management deficiencies are evident from missing findings in the audit trail reviews.
Excerpt: These findings were not included in your executed audit trail review performed for the data obtained during October, November 2022 and March 2023.
View Details
Failure to maintain a backup file of data entered into the computer or related system
Eugia SEZ Private Limited
29 Feb 2024 Normal Justification: The reliance on manual logs and the inability to verify them electronically directly points to deficiencies in the audit management process.
Excerpt: These records are managed using manual logs that could not be verified electronically during the inspection.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.